key: cord-0743279-5ayxy144
authors: Huang, Shouxiong; Tan, Ming
title: HLA class I genotypes customize vaccination strategies in immune simulation to combat COVID-19
date: 2020-11-18
journal: bioRxiv
DOI: 10.1101/2020.11.18.388983
sha: 5040af4aa66ad5c27e46d5070c7e818d63c2988d
doc_id: 743279
cord_uid: 5ayxy144

Memory CD8+ T cells are associated with a better outcome in Coronavirus Disease 2019 (COVID-19) and recognized as promising vaccine targets against viral infections. This study determined the efficacy of population-dominant and infection-relevant human leukocyte antigens (HLA) class I proteins to present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides through calculating binding affinities and simulating CD8+ T cell responses. As a result, HLA class I proteins distinguished or shared various viral peptides derived from viruses. HLA class I supertypes clustered viral peptides through recognizing anchor and preferred residues. SARS-CoV-2 peptides overlapped significantly with SARS but minimally with common human coronaviruses. Immune simulation of CD8+ T cell activation using predicted SARS-CoV-2 peptide antigens depended on high-affinity peptide binding, anchor residue interaction, and synergistic presentation of HLA class I proteins in individuals. Results demonstrated that multi-epitope vaccination, employing a strong binding affinity, viral adjuvants, and heterozygous HLA class I genes, induced potent immune responses. Therefore, optimal CD8+ T cell responses can be achieved and customized contingent on HLA class I genotypes in human populations, supporting a precise vaccination strategy to combat COVID-19.

Coronavirus disease 2019 (COVID- 19) pandemics has raised more than 55 million cases globally since earlier this year and remains rapid spreading with over a half-million new daily infections worldwide 1 . COVID-19 is caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterized as pneumonia and lymphopenia, and develops severe respiratory or multiple organ failure in around 5% of patients 2 

to provide durable T cell memory and protection up to many years after infections, such as in immune defense against SARS 4-6 , HIV 7, 8 , and influenza virus infections 9, 10 . Clinical trials of antiviral vaccines frequently led to disappointing results with weak CD8 + T cell responses 7,8,11 , supporting the importance of anti-viral CD8 + T cell responses in different human populations.

Indeed, viral-specific CD8 + T cells are essential for viral clearance and long-term protection against HIV 12 , Ebola 13 , hepatitis B viruses 14 , and cytomegalovirus 15 , despite the critical role of neutralizing antibodies for blocking viral entry to human cells 6, [16] [17] [18] . In COVID-19, it is likely important to stimulate both neutralizing antibodies and CD8 + T cell responses to achieve full protection, as in viral vaccination trials against SARS 19 and influenza virus 6, 20 . SARS-CoV-2 infections induce a dramatic reduction of CD8 + T cells associated with severe 21, 22 and elderly patients 23 . Multiple recent reports strongly support that viral-specific and memory CD8 + T cell responses are associated with milder diseases, younger patients 24 , and convalescent phases of infections 25, 26 , although HLA genotype 27 , differentiation kinetics 28, 29 , and adjuvant usage 30 impact the protection of CD8 + T cells subsets.

Activation of viral-specific CD8 + T cells and killing of viral-infected cells rely on antigenpresentation mediated by HLA class I proteins together with co-stimulation and cytokine microenvironment 31, 32 . A fundamental mechanism is that HLA class I proteins bind specific viral peptides as in a key-to-lock model 33, 34 , which interacts with the T cell receptor of CD8 + T cells Page4 for activation and viral-infected cell recognition. Similar to the cell entry of SARS-CoV 35 , SARS-CoV-2 is considered to enter lung epithelial cells and blood cells through interacting with cell surface receptors, such as angiotensin-converting enzyme 2 (ACE2), and follow the endocytic and cytoplasmic compartments 36 . Intracellular viral proteins in viral assembling and trafficking processes can be degraded in proteasome or endosome to form antigenic peptide ligands that further bind to HLA class I proteins through a secretory pathway or cross-presentation 37, 38 .

Currently, computational prediction and experimental identification of peptide antigens for CD8 + T cell activation in COVID-19 are ongoing for a purpose of "identifying vaccine candidates" 26, [39] [40] [41] . However, the impact of HLA class I genotypes on peptide antigen selection and CD8 + T cell activation remains poorly understood.

To date, the HLA-A locus displays 6291 alleles that encode around 3900 proteins, and HLA-B displays 7562 alleles that encode around 4808 proteins in humans 42 . It is unlikely to fully unveil functional CD8 + T cell responses to unique peptide sets presented by each HLA class I protein.

With a wealth of structural knowledge on HLA-peptide-T cell receptor interaction 32,43 , computational prediction and immune simulation as a prototypic artificial intelligent tool become possible and essential to facilitate structural identification and functional simulation of peptide antigen presentation for CD8 + T cell activation. This study applied affinity binding theory to predict SARS-CoV-2 peptides for binding to different HLA class I proteins and simulate the antigen-presentation process for CD8 + T cell activation. Results showed a dramatically different capacity in various HLA class I proteins to bind SARS-CoV-2 peptides.

Multiple HLA class I proteins that have been indicated to associate with more severe symptoms or weaker CD8 + T cell responses in SARS 44 were demonstrated in this study for binding a less number of SARS-CoV-2 peptides. In contrast, HLA class I proteins that have been suggested protective or potent stimulators of CD8 + T cells in SARS 45 were predicted to bind a large number of SARS-CoV-2 peptides. Different HLA class I proteins clustered to a supertype share identical sequences and similar binding patterns of SARS-CoV-2 peptides. Across various coronaviruses, a large number of peptides from SARS viruses and a limited number of peptides from "common cold"-causing human coronaviruses are identical to those of SARS-CoV-2. Further, affinitybased immune simulation provided an optimized combination of peptides dependent on HLA class I genotypes to facilitate customizing precise vaccination strategies for individuals and human populations.

To stimulate anti-COVID-19 CD8 + T cell responses, this study used NetMHCpan program to comprehensively determine the binding affinity of SARS-CoV-2 peptides to ten dominant HLA class I A and class I B proteins, which are frequently detected in the United States (US) 46 . HLA-C alleles were not involved since HLA-C proteins mainly induce immune tolerance 47 . The threshold of sufficient binding affinity was defined using a half-maximal inhibitory concentration (IC50<500nM), in which the maximal concentration of a SARS-CoV-2 peptide is required to competing off the binding of a probe peptide to each HLA class I protein. The spike (S), membrane (M), nucleocapsid (N), and multiple ORF-encoded proteins (Fig. S1A ) of the SARS-CoV-2 virus are considered immunogenic and are analyzed in this study because representative peptides of these proteins stimulate CD8 + T cells isolated from COVID-19 patients 39, 40 . Various numbers of SARS-CoV-2 peptides were predicted with a high binding affinity to ten dominant HLA class I A and B proteins (Fig. S1A) . These ten alleles exist in 78.5% of the US population approximately. Upon the further consideration of the earlier processes in antigen presentation, including proteasome degradation (cutoff>5 potential cutting sites by proteasome enzymes) 48 and peptide transportation through the transporter associated with antigen processing (TAP, cutoff IC50<1nM) 49 , 80% to 100% peptide ligands for HLA class I proteins remained significant (Fig. 1A) .

As a result, striking variation exists in the numbers of SARS-CoV-2 peptides sampled by different dominant HLA class I proteins. Most of the ten dominant HLA-A and B proteins bound high numbers of peptides derived from noted immunogenic SARS-CoV-2 proteins. A*02:01 and A*11:01 bound the highest numbers of peptides ( Fig. 1 ), indicating that a large human population expressing at least one of these dominant HLA class I alleles is able to respond to SARS-CoV-2 infection. The capacity of binding a higher number of viral peptides suggests a potential dominancy of viral-induced CD8 + T cell responses. These potent peptide binders can compensate with weak peptide binders and balance the overall ability of antigen presentation for CD8 + T cell activation, if an HLA class I genotype combines both potent and weak peptide binders in the same individual. Apparently, some SARS-CoV-2 proteins provided a lower number of peptides due to their short chain length of proteins, such as N and ORF8-encoded proteins. Thus, to estimate a critical protein source of viral peptides, peptide numbers were further normalized with the chain length of each SARS-CoV-2 protein (Fig. 1B) . As a result,

among different SARS-CoV-2 proteins, fewer percentage of peptides from N and ORF8-encoded proteins are presented by most HLA-A proteins. Among different HLA class I proteins, HLA-A proteins overall displayed a higher peptide loading capacity than HLA-B proteins. For example, HLA-A*02:01, A*11:01, and A*24:02 sampled a higher % of peptides from multiple viral proteins, except for N and ORF8-encoded proteins (Fig. 1B) . HLA-B*35:01 showed a high peptide loading capacity than other HLA-B proteins. Although the numbers of peptide ligands do not necessarily reflect the protection of peptide antigens in diseases, predicted peptides binding to HLA proteins raise a critical concern that various human populations with various HLA class I genotypes will respond differently in COVID-19 infections.

To consider whether HLA class I sequence heterogeneity selects various numbers of peptide ligands, 1 and 2 ligand-binding domains of ten HLA class I proteins were aligned (Fig. S1B ), using a hierarchical clustering approach 50 . Overall resulted similarity ranged from 75% to 96%, with the highest similarity between A*03:01 and A*11:01 (96.15%) (Fig. S1C) . However, the numbers of predicted peptides appear generally unmatched with the degree of similarity between different HLA class I proteins. For example, A*02:01 shows 92.31% similarity to A*03:01, but they have very different numbers of binding peptides for the same proteins (Fig.   1A ). Similar non-concordance occurs between A*01:01 and A*11:01 with 93.96% sequence similarity and between A*03:01 and A*11:01 with the highest sequence similarity of 96.15%.

These results suggest a need to exam the similarity of peptide-binding domains among HLA class I proteins.

To determine the conservation of viral peptides for CD8 + T cell activation in different human populations, we applied Venn diagrams to show the numbers of predicted identical peptides between dominant HLA-A proteins ( Fig. 2A) and HLA-B proteins (Fig. 2B) . We used the spike and ORF1ab genes, which encode longer protein sequences than others, to provide a higher chance of overlapped peptide sampling by different HLA class I proteins. As a result, identical peptides are infrequently shared by many HLA class I proteins despite high sequence similarity (>90%) between HLA-A or HLA-B proteins (Fig. S1C ). For some HLA proteins, vast numbers of shared peptides were observed, for example, between A*03:01 and A*11:01 with an extremely high sequence similarity of 96.15%, across B*40:01 and B*44:03 with a relatively low similarity of 89.56%, or between B*35:01 and B*07:02 with a lower sequence similarity of 88.46%. In particular, almost 80% or 85% of peptides bound to A*03:01 also bind to A*11:01. However,

HLA sequence similarity is overall discordant to the numbers of shared peptides. B*08:01 and B*07:02 (93.41% sequence similarity) shared much fewer numbers of peptides, and B*08:01 and B*40:01 (92.31% sequence similarity) shared no peptide from the S protein or only 1 out of 340 peptides from the ORF1ab-encoded proteins. Therefore, an overall high sequence similarity does not suggest a high number of peptide overlap. As in the sequence alignment (Fig. S1B ), potential determinants for the numbers of shared peptides likely originate from hot spots with limited numbers of residues in ligand-binding grooves. The similarity of these key residues and pocket structures assigns HLA class I proteins to multiple supertypes 51, 52 Further, peptide-binding motifs of HLA class I proteins interact with anchor and preferred residues of peptide ligands to achieve high binding affinity (Fig. 3) . The unique or shared anchor residues validates the binding of predicted SARS-CoV-2 peptides to specific HLA class I proteins or to HLA class I supertypes, respectively. Thus, the GibbsCluster program 53, 54 was applied to determine the residue patterns of predicted SARS-CoV-2 peptides. As a result, SARS-CoV-2 peptides showed conserved residues at positions 2 or 3 and 9, matching the reported anchor residues or preferred residues with corresponding HLA class I proteins (Fig. 3) . HLA class I proteins assigned to the same supertypes shared similar anchor and preferred residues, as for supertypes B40 (B*40:01 and B*44:03), and to a less degree for B07 (B*35:01 and B*07:02) [55] [56] [57] [58] [59] [60] .

For A*03:01 with undefined anchor and preferred residues, this study showed a similar pattern of peptide binding to A*03:01 as to A*11:01, which display a sequence similarity of 96.15% (Fig.   1C ) and belong to A03 supertype 52 . Therefore, predicted SARS-CoV-2 peptides form various patterns of anchor and preferred residues, which are shared within an HLA class I supertype ( Fig. 3) , as a unique conserved mechanism to implement HLA genotype-customized CD8 + T cell activation in various human populations.

HLA class I proteins with weak peptide binding capacity incline to associate with severe infections. Multiple HLA class I proteins have been reported to associate with more severe diseases of viral infections. In SARS infections, B*46:01 was associated with severe cases in a study using a small sample size 44 and the association of B*07:03 with severe SARS could not pass multiple tests 61 . In contrast, peptide binding to the HLA class I proteins of A03 supertype, including A*03:01 and A*11:01, was considered as potent stimulators for CD8 + T cells against Page8 SARS 45 , and the potential association of B*15:02 with resistance to SARS is not statistically significant in multiple tests 61 . Since individuals usually express two to four heterozygous or homozygous HLA class I A and B paralogous proteins, the potential association of one protein with severe diseases is likely balanced or interfered by other heterozygous HLA class I proteins in human population studies. The numbers of predicted peptide ligands in our study are supportive of a potential association of these HLA class I proteins with severity or protection of infections. For potent peptide binders potentially associated with resistance or protection, A*02:01, A*11:01, and B*15:03 sampled a large number of peptides (Fig. 4A) . These results are consistent with a common stimulator of A*11:01 for anti-SARS CD8 + T cell responses 45 peptides at low binding affinity, indicating a potential concern of weak responses in patients with an A*25:01 allele. These results allow us to predict and prepare to overcome weak peptide presenters in fighting human COVID-19 infections.

Recent tests demonstrated that non-infected healthy donors contain CD8 + T cells responding to SARS-CoV-2 peptides 39, 40 . Therefore, one can hypothesize that "common cold" coronavirus infection in humans can generate cross-reactive CD8 + T cells against SARS-CoV-2 infections.

Moreover, cross-reactivity is more prominent and much stronger between SARS and SARS-CoV-Page9 2 40 . Our predicted numbers of overlapped peptides can overall explain this cross-reactivity.

SARS and SARS-CoV-2 share various sequence similarity, such as 77.54% for S protein (Fig. S3) and 95.37% for ORF1b-encoded proteins (Fig. S4 ), contributing to the overlap of 69 peptides from spike protein and 438 peptides from ORF1b-encoded proteins between SARS with SARS-CoV-2 (Fig. 5 ). Since CD8 + T cells exposed to "common cold" coronaviruses are potentially reactive to SARS-CoV-2 peptides, the prediction of human coronavirus peptides contributing to this cross-reactivity will provide bases for cross-virus protection. However, HCoV-OC43 and SARS-CoV-2 share much lower sequence similarity at 33.06% for S protein (Fig. S3 ) and 62.32%

for ORF1b-encoded proteins, contributing to 44 shared peptides (5%) from ORF1b-encoded proteins but nearly zero shared peptide from N, S, and ORF1a-encoded proteins between HCoV-OC43 and SARS-CoV-2 (Fig. 5 ). This limited number of cross-reactive peptides from HCoV is valuable for further functional investigations for cross protection.

To predict whether high peptide binding affinity, peptide numbers, and HLA class I heterozygosity enhance CD8 + T cell responses, we use an agent-based simulator, C-ImmSim, to simulate antigen presentation for CD8 + T cell activation 63 .

C-ImmSim mainly incorporated the impact of HLA-peptide binding, innate signaling, memory responses, and adjuvant effect in antigen presentation and CD8 + T cell activation, particularly differentiating the effect of heterozygosity or homozygosity of HLA genes 63 . First, we compared CD8 + T cell responses to one versus ten peptides with a high binding affinity (IC50<16nM) without involving innate or adjuvant factors. Results showed that one peptide is insufficient, but a combination of ten peptides, stimulated CD8 + T cell responses that became saturated in around two weeks (Fig. 6A ). In this simulation, multi-epitopes stimulated more robust CD8 + T cell responses than one epitope, possibly due to very strong total binding avidity. Second, to more precisely test the avidity hypothesis, five peptides with the highest IC50 were compared with the other five peptides with the lowest IC50 as loaded to the same A*02:01 protein. Results further supported the conclusion that strong CD8 + T cell responses are more likely to be activated by multiple peptides with a high binding affinity (low IC50) to HLA class I proteins ( Fig. 6B) . Further, to determine whether heterozygous HLA-A or HLA-B proteins show an advantage to enhance CD8 + T cell responses than homozygous A*02:01 or B*44:02 alone, results showed peptides with similar or lower binding affinity stimulated stronger CD8 + T cell responses by heterozygous HLA-A or B proteins. Moreover, paralogous HLA-A and B proteins showed similar strength for CD8 + T cell activation to heterozygous HLA class I A or B proteins Page10 (Fig. 6C) . Therefore, high peptide binding affinity, HLA gene heterogeneity, and paralogous HLA-A and B proteins provide advantages to stimulate a robust CD8 + T cell response. Furthermore, the application of adjuvants such as an attenuated viral strain will help provide a cytokine environment mediated by innate cells and CD4 + T cells to facilitate the activation of peptide-specific CD8 + T cells ( Fig. 7B and 7C ). In this immune simulation, the viral adjuvant enhanced the proliferation of peptide-specific memory CD8 + T cells and balanced the production of IFN and inhibitory cytokines with extended kinetics. Therefore, a precise vaccination strategy considering potent peptide binders, heterozygous and paralogous advantages of HLA class I alleles, multi-epitopes of peptide antigens, and a viral adjuvant will induce strong anti-viral CD8 + T cell responses as tailored to individual and populational HLA class I genotypes.

More than two, three, and ten thousand HLA-A and B alleles have been detected in Asian, African, and European Americans, respectively 64 4 ). In these HLA class I supertypes, A*02:01 and A*02:02 shared more than 50% of identical peptides, and three B*15 proteins shared large numbers of identical peptides (Fig. 4) . Overlaps between paralogous HLA-A*02 and B*15 proteins also occurred at a much lower degree, implicating the presence of degenerate epitopes for CD8 + T cells 65 . Therefore, by defining HLA class I genotypes in targeted populations, similar or identical peptide antigens shared by HLA class I supertypes can be applied to vaccine design for those populations expressing HLA class I genes of the same supertypes.

Peptides with high affinity and avidity stimulate robust CD8 + T cell responses and aid weak peptide binder for T cell activation, as demonstrated by the immune simulation of antigen presentation in this study. One of our selected peptide, "FIAGLIAIV", presented by HLA-A*02:01 has been validated for the activation of T cell from SARS patients 66 . Evidence was provided with insufficiency for stimulating CD8 + T cell responses using a single peptide (Fig.   6A ) or five low-affinity peptides (Fig. 6B ) in a vaccination setting in comparison to strong responses with ten peptides or five high-affinity peptides, respectively. Therefore, a high total peptide binding affinity (or avidity) is crucial for CD8 + T cell activation in vaccination.

Heterozygosity of HLA alleles is considered as a result of balancing selection to shape exceptional polymorphism of HLA proteins and increase host immunocompetence against highly diverse pathogens 67, 68 . In this study, HLA class I heterozygosity was demonstrated to provide an advantage in presenting additional high-affinity peptides complementarily (Figs. 6 and 7). This heterozygous advantage allows the design of optimal peptide vaccination to achieve pronounced CD8 + T cell responses. For example, HLA-B*46:01 that was predicted to bind to two low-affinity peptides from ORF1ab-encoded proteins, in comparison to B*15:03 and B*07:02 predicted to bind 1538 and 158 peptides derived from the same SARS-CoV-2 proteins (Fig. 4) , likely supports the theory of heterozygous advantage 68 to elicit optimal CD8 + T cell responses, as customized to this specific HLA class I genotype (Fig.   7) . Moreover, viral co-vaccination or adjuvant can be applied to boost more robust or stabilized CD8 + T cell responses for the haplotype containing B*46:01 in human populations, together with antigen presentation mediated by either heterozygous or paralogous HLA class I A and B proteins (Fig. 7) . NetMHCpan calculates a 50% maximal inhibitory concentration (IC50) based on the maximal concentration of test peptides to compete off a probe peptide for binding to the same HLA class I protein 46 . NetMHCpan prediction has been performed accurately in recent antigen peptide prediction to integrate mass spectrometry-eluted ligands and binding affinity of peptides 70, 71 . NetMHCpan is also available for all MHC alleles to analyze dominant and disease-associated HLA class I alleles. This study used the NetMHCpan 4.0 program, which is a default method in the website of Immune Epitope Database (IEDB.org) for predicting peptide ligand binding to HLA class I proteins. This prediction was not limited to the most typical length of peptide sequence (9 amino acids) but expanded to cover a possible length of 8 to 11 residues. 4. Proteasome degradation mainly considers the degradation mediated by immune proteasomes, which are induced by Interferon  to generate antigenic peptides. Immune proteasomes degrade SARS-CoV-2 proteins to polypeptides, which have a high potential to bind to MHC Class I molecules. The prediction was based on in vitro proteasomal digestion of enolase and casein proteins as described 48 to determine the numbers of potential cutting sites at the C-termini induced by various proteasome proteases. In this Page15 prediction, we used the Netchop v3.0 "C-term" model to remove any peptides that were not predicted via proteasomal cleavage of the peptide's C terminus 72, 73 . A conserved threshold of five was used to select peptide ligands with five or more cutting sites in proteasome degradation to generate peptides for further canonical MHC class I antigen processing.

Upon proteasome digestion, cytosol peptides are required to be transported by peptide transporters across the endoplasmic reticulum membrane to be loaded to the heavy chain of HLA class I proteins. It has been shown that a high affinity of TAP transporter binding to a peptide translates into high transport rates 49 . Notably, both proteasome and TAP predictions were developed using experimental data for HLA proteins and were highly suitable for predicting viral peptide ligands for HLA class I proteins. Interestingly, TAP ligands with high binding affinity have an increased chance of being cleaved by the proteasome, and TAP specificity has evolved to fit the digestion specificity of proteasomes 73 . Thus, the prediction of TAP transporter binding to peptides links the processes of proteasome digestion and peptide loading to HLA class I proteins. A TAP score estimates -log(IC50) values (log=base 10) of peptides for binding to TAP. The cutoff of IC50 at 1 nM was used to remove peptides with higher IC50 or lower TAP binding affinity 49 .

6. Alignment of peptide residues. We align short peptides using the computational program Gibbs (http://www.cbs.dtu.dk/services/GibbsCluster/), which performs two essential tasks simultaneously, alignment and clustering 54 . We used Gibbs to deconvolute binding motifs of SARS-CoV-2 peptide datasets. GibbsCluster simultaneously clusters and aligns peptide data as a powerful tool for unsupervised motif discovery.

Results return optimal clusters with characterized sequence motifs for each cluster based on multiple parameters, including adjustable penalties for small clusters, adjustable penalties for overlapping groups, and a trash cluster to remove outliers. The results of cluster peptides are shown with the frequency of specific amino acids. The sequence motifs derived from the best solution are displayed in the form of sequence logos generated with Seq2Logo. Colors highlight different categories of amino acids, including acidic (red), basic (blue), uncharged (green), and other residues (black). The preidentified anchor and preferred residues of previously defined peptide ligands for HLA class I proteins were obtained from 

0 0 0 HLA-A HLA-B S A R S - C o V -2 SARS- CoV-2 S A R S SARS S A R S - C o V -2 SARS- CoV-2 S A R S SARS S A R S - C o V -2 SARS- CoV-2 S A R S SARS S A R S - C o V -2 SARS- CoV-2 S A R0 0 0 S A R S - C o V -2 SARS- CoV-2 S A R S - C o V -2 SARS- CoV-2 S A R S - C o V -2 SARS- CoV-2 S A R S - C o V -2 SARS- CoV-2 OC43 O C 4 3 OC43 O C 4 3 OC43 O C 4 3 OC43 O C 4 3

HCoV-OC43 Fig. 6 A. Immune simulation using different numbers of predicted peptide ligands for HLA-A*02:01 A. Numbers of predicted SARS-CoV-2 peptides for major HLA class I proteins based on peptide binding affinity. 

An interactive web-based dashboard to track COVID-19 in real time

COVID-19: immunopathology and its implications for therapy

The COVID-19 vaccine development landscape

T cell-mediated immune response to respiratory coronaviruses

Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection

T cell responses in respiratory viral infections and chronic obstructive pulmonary disease

CD8(+) T cells in HIV control, cure and prevention

The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review

Cytotoxic T-cell immunity as a target for influenza vaccines

Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Transcriptomic analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

T cell responses to cytomegalovirus

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Bioengineered Norovirus S-60 Nanoparticles as a Multifunctional Vaccine Platform

Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Traditional and new influenza vaccines

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation. bioRxiv

Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease

Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants

Mucosal-associated invariant T cells develop an innate-like transcriptomic program in anti-mycobacterial responses

Targeting Innate-Like T Cells in Tuberculosis

CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor

Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

Cell entry mechanisms of SARS-CoV-2

Activation of CD8 T Lymphocytes during Viral Infections. Encyclopedia of Immunobiology

T cell responses to viral infections -opportunities for Peptide vaccination

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

The IPD and IMGT/HLA database: allele variant databases

T cell antigen receptor recognition of antigen-presenting molecules

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation

NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence

The Dual Role of HLA-C in Tolerance and Immunity at the Maternal-Fetal Interface

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding

Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors

Multiple sequence alignment with hierarchical clustering

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

HLA class I supertypes: a revised and updated classification

Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach

GibbsCluster: unsupervised clustering and alignment of peptide sequences

Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

Peptide Motifs of Hla-A3, Hla-A24, and Hla-B7 Molecules as Determined by Pool Sequencing

Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes

The Bw4/Bw6 difference between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the stimulation of alloreactive T cells

Peptide motifs of HLA-B35 and -B37 molecules

HLA studies in the context of coronavirus outbreaks

Identifiying human MHC supertypes using bioinformatic methods

Computational Immunology Meets Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune System

High-resolution HLA alleles and haplotypes in the United States population

Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles

Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles. bioRxiv

Divergent Allele Advantage at Human MHC Genes: Signatures of Past and Ongoing Selection

HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation

The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection

NetMHCpan, a method for MHC class I binding prediction beyond humans

NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Prediction of proteasome cleavage motifs by neural networks

The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage

A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach

Alignment of ORF1b-encoded protein sequences between SARS-CoV-2 and SARS

AR LtPCasGlST DVqlRAFDIY NakVAGialh LKtNCCRFQr kDE#d#liDq %FVVKRhdls nY#rEekcY# rlKDCkaVAe HDFFkFr!#G drVPHIsRqr LTKYTMaDLc YALRHFDrn# CdlLc#ILsi YacC##dYFn

AYRLF DLVQYDFTDY KLELFNKYFK HWSMPYHPNT VDCQDDRCII Consensus KKDWYDFVEN PDIirVYanL GerfrrALlk at#FaDa$r# aGiVGVLTLD NQDLNGnWYD FGD%!qaaPG cGVa!aDSYY SliMPiLT$c rALdaElhV# n....aYrlf DLlqYDFT#e rLeLF#rYFK hWdqpYHPNc V#CqDDRCIi

Consensus HCANFN!LFS mVlPnTcFGP LVRqIFVDGV PFVVSiGYH% rELG!VhNqD V#lHrsRLSl K#LLlYAADP A$HaASanaL lDlRTcCFSV AAiTnnVaFQ TVKPGNFNqD FYDFalSKGl lKEGSSV#LK HFFFaQDGNA AIsDY#YYrY

Consensus NLPTMcDIrQ LLFVlEVVdK YF#cYDGGCI nAnQVIVNNl DKSAG%PFNK fGKARLYY#a $S%E#QDai% AYTKRNViPT iTQMNLKYAI SAKNRARTVA GVSIcSTMTn RqFHQKcLKS IAATRGapVV IGTsKFYGGW d#ML

EiVM CGGclYVKPG GTSSGDATTA %ANSVFNICQ AVsANVnAL$ Sc#GNKIaDl s!RaLQhRLY eclYRnrdVD sdFVnE%Ya% LrKHFSMMIL

Consensus nd#gqr%t#e eFYeaMYlrh aV$QaVGACV lCnSQTSLRC GaCIRrPlLC CKCCYDHVia TdHKlVLSVn PYVCNAPGCD VnDVTqLYLG GMSYYCedHK PqiSFkLcaN GqVFGLYK#s CtGSdn!dDF NaIAsCdWT# adDYILANeC 1051

Consensus TERLKLFAAE TqKATEEaFK qSYaiAT!rE !lS#RELhLS WE!GKprPPL NrNYVFTGYr fTKNgKtqiG EYtF#Kg#lg #aVyYRaTTT YKLnVGDyFV LTSHsVanLS aPTLVPQEnY srIr

Consensus YcTlQGPPGT GKSHlAIGLA l%YcsAR!VY TAaSHAAVDA LCEKAlK%Ln I#dCsRI!PA raRVEC%DKF K!NdTlrqYV FcT!NALPEm taDIVVfDE! SMaTNY#LSV !NARiRAKHY VYIGDPAQLP APRtLLsKGT LEPeYFNsVc

Consensus rLMcciGPDi FLGTCrRCPa EIVDTVSALV Y#NKLKAhn# kSaqCFKm%Y KGViTH#sSS A!NrqQIgl! reFLkaNPaW rKAVFISPYN SQNaaAkr!L GLqTQTVDSa QGSEYDYVI% sQTaETAHSc NVNRFNVAIT RAKkGILC!M 1501

Consensus S#r#L%#aLQ FTsLeidrrn qAt.lqa#ns TnLFKDCSKs isGlHPaqAP shLaVDdK%K aeGdcadclG Igdd.mTYrR LIS$MGFK$# yql#GYcn$F ITrEEA!rrV RAW!GFDaEG aHATR#a!GT NlPLQLGFST G!#lVaeaTG 1651

Consensus lfadr#ntdF krasAKaPPG #QFKHLIPLM trGhrW#VVR irIVQMlaDh Li#LSDrVVl VlWAanFELT c$rYFaK!Gr ErsCnlCdrR ATc%nsasdt YaCWrHS!gc DYlYNPli!D !QQWG%iGnL qSNHDLYCqV HgnAHVAScD

VKSV KTLLYSFEAH KDSFKDGLCM FWNCNVDKYP PNAVVCRFDT RVLNNLNLPG CNGGSLYVNK Consensus AIMTRCLAVh #CFcnr!#Wn !EYPIIg#EL kINaaCRklQ rm!lKAA$La #r%plchDIG NPKAIaCVk

akk! eeLlYS%aaH kDkFkDGlC$ FWNCNVDrYP aNa!VCRFDT RVLnNLNLPG C#GGSLYVNK

Consensus HAFHTkaFar aAFenLKq$P FFYYSDsPCe shdgqdak#! DYVPLKSATC ITRCNLGGAV CrhHA#EYRe YL#aYNmais AGFslWVYKq FDfYNLWNTF TrLQSLENVa %NlVnkGH%d GQaGEmPcaI IN#kVyaK!D geDVeiFeNn 2101

Fnq%dkl

TiFTQSRniq eFkcRs#MEi DFiaLaqDeF I#rYgLEdYA FEHIVYG#Fn qkqiGGLHLL IGLarRqqeS nlel##F!pm DSs!hnYFIT DaqsGgSKcV CsVIDiLLDD FVai!KSq#L